Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Apr 21, 2011

Premium

Title: Polyamides for Nucleic Acid Delivery

Patent Number: 7,927,873

Filed: Dec. 20, 2004

Inventor: Theresa Reineke, University of Cincinnati

The invention, the patent's abstract states, “provides a new class of non-viral transduction vectors that can be used for both in vivo and in vitro applications … [as well as] a gene transfer vector that has comparable efficiency to a viral vector without the potential for a life-threatening immune response.

“Complexes according to the invention or portions thereof can comprise a cellular delivery molecule or agent that can facilitate the translocation of the complex or portion thereof into cells,” the abstract states. “In some embodiments, cellular delivery molecules for use in the ... invention may comprise one or more polymers.”


Title: H19-Silencing Nucleic Acid Agents for Treating Rheumatoid Arthritis

Patent Number: 7,928,083

Filed: Jan. 16, 2008

Inventor: Abraham Hochberg, Hebrew University of Jerusalem

“The invention relates to the treatment of rheumatoid arthritis, particularly to the use of nucleic acid agents capable of silencing H19 for the treatment of rheumatoid arthritis,” according to the patent's abstract. “The invention provides methods for ameliorating rheumatoid arthritis and symptoms associated therewith, utilizing gene silencing oligonucleotides such as small interfering RNA agents directed to H19.”


Title: Nuclease-Resistant Double-Stranded Ribonucleic Acid

Patent Number: 7,928,217

Filed: May 27, 2005

Lead Inventor: Hans-Peter Vornlocher, Alnylam Pharmaceuticals

“This invention relates to modified double-stranded oligoribonucleic acid having improved stability in cells and biological fluids, and methods of making and identifying dsRNA having improved stability, and of using the dsRNA to inhibit the expression or function of a target gene,” the patent's abstract states.


Title: RNA Interference-Mediated Inhibition of Polycomb Group Protein EZH2 Gene Expression Using Short Interfering Nucleic Acid

Patent Number: 7,928,218

Filed: July 2, 2008

Lead Inventor: James McSwiggen, Merck

“This invention relates to compounds, compositions, and methods useful for modulating polycomb group protein EZH2 gene expression using short interfering nucleic acid molecules,” the patent's abstract states. “This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of polycomb group protein EZH2 gene expression and/or activity by RNA interference using small nucleic acid molecules.”


Title: RNA Interference-Mediated Inhibition of Placental Growth Factor Gene Expression Using Short Interfering Nucleic Acid

Patent Number: 7,928,219

Filed: July 10, 2008

Lead Inventor: James McSwiggen, Merck

The invention, the patent's abstract states, “relates to compounds, compositions, and methods useful for modulating placental growth factor gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of placental growth factor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules.”


Title: RNA Interference-Mediated Inhibition of Stromal Cell-Derived Factor-1 Gene Expression Using Short Interfering Nucleic Acid

Patent Number: 7,928,220

Filed: March 16, 2010

Lead Inventor: James McSwiggen, Merck

“The invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of stromal cell-derived factor-1 gene expression and/or activity,” the patent's abstract states. The invention is also directed to “compounds, compositions, and methods relating to traits, diseases, and conditions that respond to the modulation of expression and/or activity of genes involved in SDF-1 gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases, and conditions. Specifically, the invention relates to small nucleic acid molecules … that mediate RNA interference against SDF-1 gene expression. Such small nucleic acid molecules are useful, for example, in providing compositions for treatment of traits, diseases, and conditions that can respond to modulation of SDF-1 expression in a subject, such as ocular disease, cancer and proliferative diseases, and any other disease, condition, trait, or indication that can respond to the level of SDF-1 in a cell or tissue.”


Title: Process for Predicting the Prognosis of Squamous Cell Lung Cancer

Patent Number: 7,927,805

Filed: Oct. 30, 2008

Lead Inventor: Mitch Raponi, Veridex

The invention, the patent's abstract states, comprises “a method for predicting the prognosis of squamous cell lung cancer by observing regulatory changes in select miRNA sequences. These sequences may include hsa-mir-146b, hsa-mir-191, hsa-mir-206, hsa-mir-299-3p, hsa-mir-155, hsa-mir-15a, hsa-mir-122a, hsa-mir-513, hsa-mir-184, hsa-mir-511, hsa-mir-100, hsa-mir-10a, hsa-mir-453, hsa-mir-379, hsa-mir-202, hsa-mir-21, hsa-mir-126, hsa-mir-494, hsa-mir-432, hsa-mir-370, and combinations of these sequences.”


Title: Delivery of siRNAs

Application Number: 20110086425

Filed: June 18, 2010

Inventor: Tariq Rana, University of Massachusetts

The invention comprises “siRNA delivery methods [for] use in vivo or in vitro,” the patent application's abstract states. “The delivery methods include conjugation with delivery peptides and mixing with dendrimers.”


Title: Identification of microRNAs in Fecal Samples as Biomarkers for Gastroenterological Cancers

Application Number: 20110086353

Filed: Oct. 8, 2010

Lead Inventor: Ajay Goel, Baylor Research Institute

The invention, the patent application's abstract states, comprises a “simple, rapid, inexpensive, and promising commercial biomarker assay method for multiple diseases. The invention detects miRNA-based biomarkers in human stool specimens … [by ampifying] miRNA directly from stool specimens without any prior miRNA extraction.

“Differential expression of specific microRNAs in stool of colorectal cancer and adenoma patients suggest fecal microRNAs as a novel potential biomarker for colorectal neoplasia detection,” it adds. “The method of the ... invention has diagnostic, prognostic, and therapeutic relevance for gastroenterological cancers/colorectal cancer ... as well as further acquired or hereditary GI diseases.”

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.